New lithium formula tested for brain uptake in healthy adults
NCT ID NCT06921590
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This early-stage study tests a new crystallized form of lithium (AL001) against standard lithium carbonate in 6 healthy adults. Participants take each drug for 14 days and undergo MRIs and blood draws to compare how much lithium reaches the brain. The goal is to see if AL001 is safer or more effective at targeting the brain, which could help future treatments for conditions like bipolar disorder.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.